Protara Therapeutics Inc

Protara Therapeutics insider sales stay within industry norms, align with Rule 10b‑5‑1, and signal disciplined liquidity management ahead of earnings and clinical milestones.

Protara Therapeutics insider trades reveal executive confidence in TARA‑002’s market access, highlighting how upcoming Phase‑2 data could boost pricing strategy and competitive positioning in bladder‑cancer immunotherapy.